Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP98 | DOI: 10.1530/endoabs.41.EP98

ECE2016 Eposter Presentations Bone & Osteoporosis (40 abstracts)

From EFOS to ExFOS, active treatment phase – similarities and differences of the Greek cohorts’ results

Kyriakos Aloumanis 1 , Panagiotis Kokkoris 2 , Andreas Kleisiounis 3 , Evanthia Kofini 1 , Konstantinos Karachalios 1 , Vangelis Drossinos 1 & Georgios Kapetanos 4


1Department of Medical Research, Pharmaserve-Lilly SACI, Kifissia Athens, Greece; 2Private office, Athens, Greece; 3Private office, Chalkida, Greece; 43rd Orthopedics University Clinic, Papageorgiou General Hospital, Thessaloniki, Greece.


Introduction: Extended Forsteo® Observational Study (ExFOS), a multinational, non-interventional, prospective, observational study, designed to evaluate fractures, back pain (BP), adherence and health-related quality of life (QoL) in teriparatide (TPTD) treated patients, based on the extension of treatment duration (24 months) and the addition of new indications (glucocorticoid-induced and male osteoporosis) was compared with EFOS.

Methods/design: Baseline data showed that Hellenic EFOS patients share similarities and noticeable differences with female ExFOS patients1. To further evaluate such similarities/differences between the two studies, we aimed to compare the active treatment results of the Greek cohorts between EFOS2 (n=301, all female) and ExFOS (n=416, 92.1% female). No statistical comparisons between studies were performed.

Results: Approximately 80% of patients in both cohorts were on treatment one month before maximum treatment period. Lumbar T-score (mean+SD) increased from −3.46±0.67 (n=175) at baseline to −2.54±0.74 (n=120) at study end in EFOS and from -3.39±0.73 (n=263) to −2.36±0.63 (n=78) in ExFOS. QoL and BP parameters had similar improvements, as shown by examples depicted below:

Baseline3 m6 m12 m18 m24 m
BP (in previous month)
ExFOS86.2%79.3%72.2%65.6%59.2%42.2%
EFOS93.2%84.6%77.8%66.4%64.2%
BP frequency (every/almost every day)
ExFOS43.8%12.4%6.6%4.3%4.7%0%
EFOS39.9%7.5%3.9%2.5%2.2%
BP severity (moderate/severe)
ExFOS76.2%50.4%32.8%20.9%22.2%18.6%
EFOS89.9%69.4%50.7%42.4%32.4%
EQ-5D Mobility (some/extreme problems)
ExFOS57.9%38.9%29.9%22.5%17.7%16.2%
EFOS62.3%36.7%24.0%18.3%14.8%
EQ-5D VAS
ExFOS576671757783
EFOS5464697480

Conclusions: Two similarly designed studies, in comparable Hellenic populations, yielded similar results that should be interpreted in the context of observational studies.

References: 1BMC Musculoskelet Disord. 2015;16:136.

2J Osteoporos. 2011;2011:510398.

Article tools

My recent searches

No recent searches.